使用剂量-体积直方图预测行 Y-90 树脂微球经肝动脉放射性栓塞术的肝癌患者代谢反应。
Use of dose-volume histograms for metabolic response prediction in hepatocellular carcinoma patients undergoing transarterial radioembolization with Y-90 resin microspheres.
机构信息
Department of Nuclear Medicine, Ankara Yildirim Beyazit University, Ankara, Turkey.
Department of Nuclear Medicine, Ankara Bilkent City Hospital, Cankaya, Ankara, Turkey.
出版信息
Ann Nucl Med. 2024 Jul;38(7):525-533. doi: 10.1007/s12149-024-01926-4. Epub 2024 Apr 22.
INTRODUCTION
Voxel-based dosimetry offers improved outcomes in the treatment of hepatocellular carcinoma (HCC) with transarterial radioembolization (TARE) using glass microspheres. However, the adaptation of voxel-based dosimetry to resin-based microspheres has been poorly studied, and the prognostic relevance of heterogeneous dose distribution remains unclear. This study aims to explore the use of dose-volume histograms for resin microspheres and to determine thresholds for objective metabolic response in HCC patients treated with resin-based TARE.
METHODS
We retrospectively reviewed HCC patients who underwent TARE with Y-90-loaded resin microspheres in our institution between January 2021 and December 2022. Voxel-based dosimetry was performed on post-treatment Y-90 PET/CT images to extract parameters including mean dose absorbed by the tumor (mTD), the percentage of the targeted tumor volume (pTV), and the minimum doses absorbed by consecutive percentages within the tumor volume (D10, D25, D50, D75, D90). Assessment of metabolic response was done according to PERCIST criteria with F-18 FDG PET/CT imaging at 8-12 weeks after the treatment.
RESULTS
This study included 35 lesions targeted with 22 TARE sessions in 19 patients (15 males, 4 females, mean age 60 ± 13 years). Objective metabolic response was achieved in 43% of the lesions (n = 15). Responsive lesions had significantly higher mTD, pTV, and D25-D90 values (all p < 0.05). Optimal cut-off values for mTD, pTV, and D50 were 94.6 Gy (sensitivity 73%, specificity 70%, AUC 0.72), 94% (sensitivity 73%, specificity 55%, AUC 0.64), and 91 Gy (sensitivity 80%, specificity 80%, AUC 0.80), respectively.
CONCLUSION
Parameters derived from dose-volume histograms could offer valuable insights for predicting objective metabolic response in HCC patients treated with resin-based TARE. If verified with larger prospective cohorts, these parameters could enhance the precision of dose distribution and potentially optimize treatment outcomes.
简介
基于体素的剂量学在使用玻璃微球进行经动脉放射性栓塞(TARE)治疗肝细胞癌(HCC)方面提供了更好的结果。然而,基于树脂的微球的基于体素的剂量学的适应性研究甚少,并且异质剂量分布的预后相关性尚不清楚。本研究旨在探索使用树脂微球的剂量-体积直方图,并确定使用树脂基 TARE 治疗的 HCC 患者客观代谢反应的阈值。
方法
我们回顾性分析了 2021 年 1 月至 2022 年 12 月期间在我院接受 Y-90 负载树脂微球 TARE 的 HCC 患者。在治疗后 Y-90 PET/CT 图像上进行基于体素的剂量学,提取参数包括肿瘤吸收的平均剂量(mTD)、靶肿瘤体积(pTV)的百分比和肿瘤体积内连续百分比吸收的最小剂量(D10、D25、D50、D75、D90)。根据 PERCIST 标准,在治疗后 8-12 周用 F-18 FDG PET/CT 成像评估代谢反应。
结果
本研究包括 19 名患者(15 名男性,4 名女性,平均年龄 60±13 岁)的 22 次 TARE 治疗的 35 个病灶。43%的病灶达到了客观代谢反应(n=15)。有反应的病灶 mTD、pTV 和 D25-D90 值明显更高(均 p<0.05)。mTD、pTV 和 D50 的最佳截断值分别为 94.6Gy(敏感性 73%,特异性 70%,AUC 0.72)、94%(敏感性 73%,特异性 55%,AUC 0.64)和 91Gy(敏感性 80%,特异性 80%,AUC 0.80)。
结论
来自剂量-体积直方图的参数可为预测使用树脂基 TARE 治疗的 HCC 患者的客观代谢反应提供有价值的信息。如果用更大的前瞻性队列进行验证,这些参数可以提高剂量分布的精度,并可能优化治疗结果。